Stakeholder | Date(s) issued | Ovarian cancer recommendations | Uterine cancer recommendations |
Society of Gynecologic Oncology (SGO) | 2014 | Genetic counseling and testing for all ovarian, fallopian tube, peritoneal cancers[1] | Joint ACOG/SGO recommendations: Tumor testing for MSI/MMR IHC on any endometrial or colorectal tumor from a woman at risk for Lynch syndrome by focused personal and family medical history, or all endometrial cancers age <60. Germline testing for marker expression loss on tumor tissue.[4]
|
American College of Obstetricians and Gynecologists (ACOG) | 2009 | Patients with greater than an approximate 20 to 25% chance of having a mutation[2] | |
National Society of Genetic Counselors (NSGC) [Joint with the American College of Medical Genetics and Genomics (ACMG)] | 2014 | Single case of ovarian, fallopian tube, or peritoneal cancer present in the patient or a first-degree relative[3] |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟